The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | PARCT: atezolizumab for CTCL and next steps
Rudolf Stadler, MD, PhD, University Medical Center Minden, Minden, Germany, gives an update on the Phase II PARCT trial (NCT03357224) investigating the PD-L1 inhibitor atezolizumab for the treatment of stage IIb-IV mycosis fungoides or Sézary syndrome, for patients who become relapsed/refractory (R/R) after a previous systemic treatment. Prof. Stadler discussess challenges around the safety profile of atezolizumab and the need to find biomarkers which enable the identification of patients who would benefit the most from this therapy. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
